« Previous AbstractProducts and mechanism of secondary organic aerosol formation from reactions of n-alkanes with OH radicals in the presence of NOx    Next AbstractQuantitative evaluation of total volatile organic compounds in urban and rural schools of southern Brazil »

Cancers (Basel)

Title:		A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers
Author(s):		Lima AR; Pinto J; Carvalho-Maia C; Jeronimo C; Henrique R; Bastos ML; Carvalho M; Guedes de Pinho P;
Address:		"UCIBIO/REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal. Cancer Biology & Epigenetics Group, Research Center (CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal. Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), P.CCC Porto Comprehensive Cancer Center, 4200-072 Porto, Portugal. Department of Pathology and Molecular Immunology, Biomedical Sciences Institute (ICBAS), University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal. Fernando Pessoa Energy, Environment and Health Research Unit (FP-ENAS), Faculty of Health Sciences, University Fernando Pessoa, 4249-004 Porto, Portugal"
Journal Title:		Cancers (Basel)
Year:		2020
Volume:		20200723
Issue:		8
Page Number:		-
DOI:		10.3390/cancers12082017
ISSN/ISBN:		2072-6694 (Print) 2072-6694 (Electronic) 2072-6694 (Linking)
Abstract:		"Our group recently developed a urinary 6-biomarker panel for the diagnosis of prostate cancer (PCa) which has a higher level of accuracy compared to the serum prostate specific antigen (PSA) test. Herein, urine from an independent cohort of PCa patients and cancer-free controls was analyzed to further validate the discriminative power of that panel. Additionally, urine from patients diagnosed with bladder cancer (BC) and renal cancer (RC) were included to evaluate the site-specificity of the panel. Results confirmed the ability of the 6-biomarker panel to discriminate PCa patients from controls, but not from other urological cancers. To overcome this limitation, an untargeted approach was performed to unveil discriminant metabolites among the three cancer types. A 10-biomarker panel comprising the original panel plus four new metabolites was established to discriminate PCa from controls, BC, and RC, with 76% sensitivity, 90% specificity, and 92% accuracy. This improved panel also disclosed better accuracy than serum PSA test and provides the basis for a new non-invasive early detection tool for PCa"
Keywords:		bladder cancer detection prostate cancer renal cancer urinary biomarkers volatile organic compounds;
Notes:		"PubMed-not-MEDLINELima, Ana Rita Pinto, Joana Carvalho-Maia, Carina Jeronimo, Carmen Henrique, Rui Bastos, Maria de Lourdes Carvalho, Marcia Guedes de Pinho, Paula eng UIDB/04378/2020/Fundacao para a Ciencia e a Tecnologia/ Switzerland 2020/07/29 Cancers (Basel). 2020 Jul 23; 12(8):2017. doi: 10.3390/cancers12082017"